Journals / Glokom Katarakt / 2013 / Cilt: 8 - Sayı: 4

Assessment of the effectiveness and alternatives of treatment in neovascular glaucoma

Neovasküler glokomda tedavi seçenekleri ve etkinliklerinin değerlendirilmesi

Pages
249–252
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intravitreal anti-VEGF injection before MMC trab is an efficient treatment modalitiy to enhance the surgical success.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To determine the demographic characteristics of the patients that were followed in our clinic with the diagnosis of neovascular glaucoma (NVG), to investigate the factors that have role in the etiology and the effects of treatment modalities on intraocular pressure (IOP).
📊
Key Findings & Data:Materials and Methods: Ninety-nine eyes of 96 patients with NVG included in the study.
💡
Conclusion & Impact:Intravitreal anti-VEGF injection before MMC trab is an efficient treatment modalitiy to enhance the surgical success.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To determine the demographic characteristics of the patients that were followed in our clinic with the diagnosis of neovascular glaucoma (NVG), to investigate the factors that have role in the etiology and the effects of treatment modalities on intraocular pressure (IOP). Materials and Methods: Ninety-nine eyes of 96 patients with NVG included in the study. The demographical character- istics of patients, factors that have a role in the etiology and the results of the treatment methods were analyzed from the patients’ files retrospectively. Results: Of the patients included in the study, the mean age of the patients was 65.8±7.8 years and the mean follow-up time was 33.6±6.4 months. Diabetes mellitus (DM) in 54 eyes (54.54%), central retinal vein occlusion (CRVO) in 28 eyes (28.28%), trauma in nine eyes (9.09%), and uveitis in eight eyes (8.08%) were found to be the reason for the NVG. Postecva- torial cryotherapy and syclocryotherapy were performed to 58 eyes (77.33%), trabeculectomy with mitomycin C (MMC trab) was performed to 11 eyes (14.66%), MMC trab after intravitreal anti-VEGF injection was performed to five eyes (6.66%), and Ahmed valve implantation was performed to one eye (1.33%). The reduction of mean IOP for each procedure was statisti- cally significant (p<0.05). Conclusion: DM and CRVO have an important role in the etiology of NVG. It is thought that MMC trab performed in the treatment of this disorder can cause benefit in most of the patients. Intravitreal anti-VEGF injection before MMC trab is an efficient treatment modalitiy to enhance the surgical success.

Özet

Amaç: Neovasküler glokom (NVG) tanısıyla kliniğimizde takip edilen hastaların demografik özelliklerini belirlemek, etiyo- lojide rol oynayan faktörleri ve uygulanan tedavi yöntemlerinin göz içi basıncına (GİB) etkisini araştırmak. Gereç ve Yöntem: Doksan altı NVG’li hastanın 99 gözü çalışma kapsamına alındı. Hasta dosyalarından hastaların demog- rafik özellikleri, etiyolojide rol oynayan faktörler ve uygulanan tedavi yöntemlerinin sonuçları retrospektif olarak incelendi. Bulgular: Çalışmaya dahil olan hastaların yaş ortalaması 65.8±7.8 yıl ve ortalama takip süreleri 33.6±6.4 ay idi. Neovas- küler glokoma 54 gözde (%54.54) diyabetes mellitüs (DM), 28 gözde (%28.28) santral retinal ven tıkanıklığı (SRVT), dokuz gözde (%9.09) travma ve sekiz gözde (%8.08) üveitin neden olduğu izlendi. Elli sekiz göze (%77.33) siklokriyoterapi ve postekvatoriyal kriyoterapi, 11 göze (%14.66) mitomisin-C’li trabekülektomi (MMC trab), beş göze (%6.66) intravitreal anti- VEGF enjeksiyonu sonrasında MMC trab ve bir göze (%1.33) Ahmed valv implantasyonu operasyonu uygulandı. Uygulanan tüm prosedürlerdeki ortalama GİB düzeyindeki azalma istatistiksel olarak anlamlıydı (p<0.05). Sonuç: Neovasküler glokomun etiyolojisinde DM ve SRVT önemli rol oynamaktadır. Tedavide uygulanacak MMC trab ile hastaların çoğunda fayda sağlanabileceği düşünülmektedir. MMC trab öncesi uygulanan intravitreal anti-VEGF enjeksiyo- nu ise cerrahi başarıyı arttıran etkin bir tedavi yöntemidir.

🔖

Cite This Article

ULUSOY, D. M., EVREN, Ö. K., DURU, N. (2013). Assessment of the effectiveness and alternatives of treatment in neovascular glaucoma. Glokom Katarakt, Cilt: 8 - Sayı: 4, 249–252. https://ajindex.com/articles/210891

References (17)

  1. Johnson M, Gong H, Freddo TF, et al. Serum proteins and aqueous outflow resistance in bovine eyes. Invest Ophthalmol Vis Sci 1993
  2. Kubota T, Tawara A, Hata Y, et al. Neovascular tissue in the intertra- becular spaces in eyes with neovascular glaucoma. Br J Ophthalmol 1996
  3. Tripathi RC, Li J, Tripathi BJ, et al. Increased levels of vascular en- dothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998
  4. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovasculariza- tion after intravitreal injection of bevacizumab in patients with prolifera- tive diabetic retinopathy. Am J Ophthalmol 2006
  5. Barkmeier AJ, Akduman L. Bevacizumab (Avastin) in ocu- lar processes other than choroidal neovascularization. Ocular Immunulogy&Inflammation 2009
  6. Madsen PH. Experiences in surgical treatment of haemorrhagic glau- coma. A follow-up study. Acta Ophthalmol Suppl 1973
  7. Brown GC, Maqarqal LE, Schachat A, et al. Neovascular glaucoma. Etio- logic consideration. Ophthalmology 1984
  8. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007
  9. Kanski JJ. Clinical Ophthalmology. A systematis Approach Neovascular Glaucoma., Second edition, Buttirworth Neinemann Ltd 1989
  10. p:216-7. 10.Wand M: Neovascular glaucoma in. the Glaucoma. Ritch R, Shield MB, Krupin T, eds. The C.V. Mosby company, st Louis, Baltimore, Philadel- phia Toronto 1989
  11. p:1073-129. 11.Wand M. Neovascular glaucoma. Jacobiec FA, Albert DM eds. W.B. Saunders Company, Philadelphia 1994
  12. p:1485-505. 12.Sivak-Callcott JA, O’Day DM, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmol- ogy 2001
  13. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006
  14. Pavan PR, Folk JC, Weingeist TA, et al. Diabetic rubeosis and panretinal photocoagulation. Arch Ophthalmol 1983
  15. Striga M, Ivanisevic M. Comparison between efficacy of full- and mild- scatter (panretinal) photocoagulation on the course of diabetic rubeosis iridis. Ophthalmologica 1993
  16. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovasculariza- tion after intravitreal injection of bevacizumab in patients with prolifera- tive diabetic retinopathy. Am J Ophthalmol 2006
  17. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosi